Karachi: GlaxoSmithKline Pakistan Limited has announced that its Board of Directors will convene a meeting on October 29, 2026, at 12 noon in Karachi and via video link. The meeting's agenda is to consider the financial results for the quarter ending September 30, 2026.

The company has instituted a closed period from October 22, 2026, through October 29, 2026, in accordance with clause 5.6.d4 of the Pakistan Stock Exchange rule book. During this period, key company figures, including Directors, the Chief Executive Officer, the Chief Financial Officer, the Company Secretary, substantial shareholders, other executives, and their spouses, are prohibited from trading in company shares.

According to information available from the Pakistan Stock Exchange (PSX), this measure ensures compliance with regulatory requirements and aims to prevent any potential misuse of insider information.

GlaxoSmithKline Pakistan Limited operates within the pharmaceutical sector and is committed to adhering to the regulations set forth by the PSX to maintain market integrity and investor confidence.